J. Donald deBethizy
Chairman since 2018
J. Donald deBethizy (born 1950) has more than 30 years of biopharmaceutical industry experience including as an entrepreneur, CEO and board member. In addition to serving as Chairman of Saniona’s board of directors, he also currently serves as Chairman of the board of directors for Albumedix Ltd. and as a member of the board of directors for argenx N.V., Lophora ApS, Newron Pharmaceuticals SpA, Noxxon NV and Proterris, Inc. He is also a member of management (direktion) of Albumin Holding ApS and White City Consulting ApS.
Previously, deBethizy served as chair of Rigontec GmbH until it was sold to Merck Inc. Prior to that, he served as CEO of Santaris Pharma A/S, until its acquisition by Roche Holdings. Prior to these positions, he served he served as executive chair of the Danish biotech Contera Pharma A/S until it was sold to Bukwang Pharma Co Ltd. Before that, he served as co-founder and CEO of Targacept, Inc., which was publicly traded on Nasdaq and later sold to Catalyst Biosciences. Before founding Targacept, deBethizy served in various positions with RJ Reynolds for 15 years. He received his Ph.D. and M.Sc. in toxicology from Utah State University and a B.Sc. in biology from the University of Maryland. Additional previous board positions have included Novozymes Biopharma DK A/S, Asceneuron SA, Biosource Inc., Enbiotix Inc., LigoCyte Pharmaceuticals Inc., Serenova A/S (previously Serendex Pharmaceuticals A/S) and Targacept.
deBethizy is independent in relation to both Saniona and its management as well as major shareholders. He holds 12,500 shares and 217,625 warrants in the warrant program 2018/2024.